✦ LIBER ✦

Activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR [KDR]-TKI), in a model of ZD1839 (‘Iressa’) resistance

Book ID: 117659534
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 275 KB
Volume: 38
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(02)80842-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Anticancer effects of ZD6474, a VEGF rec

Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib (“Iressa”)-sensitive and resistant xenograft models

✍ Fumiko Taguchi; Yasuhiro Koh; Fumiaki Koizumi; Tomohide Tamura; Nagahiro Saijo; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 917 KB

Pharmacokinetics of single and multiple

Pharmacokinetics of single and multiple oral doses of zd 1839 (‘Iressa’), a specific epidermal growth factor receptor tyrosine kinase inhibitor (egfr-tki), in healthy male volunteers

✍ H.C. Swaisland; R. Smith; H. Jones; J. Farebrother; A. Laight 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 184 KB

Antitumor activity of the selective epid

Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa® (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo

✍ Ichiro Naruse; Tohru Ohmori; Yoko Ao; Hisao Fukumoto; Toshio Kuroki; Masatomo Mo 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 216 KB 👁 1 views

## Abstract Selective tyrosine kinase inhibitors are regarded as promising antitumor agents for cancer treatment. Iressa® (ZD1839) is an orally active, selective EGFR‐TKI (epidermal growth factor receptor‐tyrosine kinase inhibitor) that blocks signal transduction pathways implicated in cancer cell

Preclinical rationale for a combined tre

Preclinical rationale for a combined treatment with irinotecan and the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (Iressa) in irinotecan-refractory human colon cancer

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 157 KB

A Multicenter Phase II Trial of ZD6474,

A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Previously Treated Metastatic Breast Cancer

✍ Dickler, M.N. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB

ZD1839 (Iressa), a novel epidermal growt

ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression

✍ Neil G. Anderson; Tawhid Ahmad; Kai Chan; Richard Dobson; Nigel J. Bundred 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 192 KB 👁 1 views

Overexpression of the growth factor receptors EGFR and erbB2 occurs frequently in several human cancers and is associated with aggressive tumour behaviour and poor patient prognosis. We have investigated the effects of ZD1839 (Iressa), a novel EGFR tyrosine kinase inhibitor, on the growth, in vitro